First Wave BioPharma Renamed Entero Therapeutics

Entero Therapeutics, Inc., previously known as First Wave BioPharma, Inc., has announced a significant rebranding and unveiled a new corporate identity and website. This initiative follows a business merger with ImmunogenX and underscores the company’s commitment to addressing unmet needs in gastrointestinal (GI) health, particularly through the development of targeted, non-systemic therapies for GI diseases. Entero’s common stock will begin trading on Nasdaq under the new ticker symbol "ENTO" starting May 17, 2024.

The rebranding is a strategic move aligning with Entero’s mission of bringing innovative treatments to the market for gut and intestinal health. According to James Sapirstein, Chairman and CEO of Entero Therapeutics, the addition of latiglutenase to their pipeline provides an opportunity to address significant medical needs and market opportunities, particularly for celiac disease, a condition for which there are currently no approved medical treatments.

Latiglutenase, a promising biotherapeutic, consists of two gluten-specific recombinant proteases. It has shown efficacy in reducing GI symptoms and protecting against intestinal damage in celiac disease patients during three Phase 2 clinical trials. The Phase 3 clinical plan for latiglutenase has received approval from the GI Division of the FDA, with the trial expected to commence in early 2025.

In conjunction with Celiac Awareness Month in May, Entero is collaborating with Celiac Journey, a patient advocacy organization, to promote awareness through a digital display on the Nasdaq Tower in Times Square. This display will be featured at 4:25 p.m. ET and will also participate in the global "Shine a Light on Celiac Disease" initiative, which illuminates famous landmarks in green.

Entero Therapeutics is a late clinical-stage biopharmaceutical firm concentrated on creating targeted, non-systemic treatments for GI diseases. Their pipeline includes several noteworthy programs: latiglutenase, a Phase 3-ready oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for conditions including gastroparesis; and adrulipase, a recombinant lipase enzyme aimed at facilitating the digestion of fats and other nutrients in patients with cystic fibrosis and chronic pancreatitis who suffer from exocrine pancreatic insufficiency.